Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3047% below fair value
$2.88−0.15 (-4.95%)
Close on Nov 17, 2026Market cap $232.05MP/E 12.5Yield –
Protalix BioTherapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Protalix BioTherapeutics's revenue for the twelve months ending Jun 30, 2026 was $80.62M, up 30.1% year over year. For fiscal 2025 it was $52.74M, down 1.2% from the year before. Over ten years it grew 28.3% a year on average. The highest annual figure on record is $65.49M in fiscal 2023.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.74M | -1.2% |
| FY2024 | Dec 31, 2024 | $53.40M | -18.5% |
| FY2023 | Dec 31, 2023 | $65.49M | +37.5% |
| FY2022 | Dec 31, 2022 | $47.64M | +24.2% |
| FY2021 | Dec 31, 2021 | $38.35M | -39.0% |
| FY2020 | Dec 31, 2020 | $62.90M | +15.0% |
| FY2019 | Dec 31, 2019 | $54.69M | +59.7% |
| FY2018 | Dec 31, 2018 | $34.24M | +62.4% |
| FY2017 | Dec 31, 2017 | $21.08M | +129.1% |
| FY2016 | Dec 31, 2016 | $9.20M | +110.8% |
| FY2015 | Dec 31, 2015 | $4.36M | +23.9% |
| FY2014 | Dec 31, 2014 | $3.52M | – |
| FY2013 | Dec 31, 2013 | $0 | -100.0% |
| FY2012 | Dec 31, 2012 | $34.87M | +315.8% |
| FY2011 | Dec 31, 2011 | $8.39M | +26.3% |
| FY2010 | Dec 31, 2010 | $6.64M | +1611.9% |
| FY2009 | Dec 31, 2009 | $388.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $19.90M | +27.1% |
| Q1 FY2026 | Mar 31, 2026 | $33.75M | +233.7% |
| Q4 FY2025 | Dec 31, 2025 | $9.12M | -49.9% |
| Q3 FY2025 | Sep 30, 2025 | $17.85M | -0.6% |
| Q2 FY2025 | Jun 30, 2025 | $15.66M | +16.2% |
| Q1 FY2025 | Mar 31, 2025 | $10.11M | +169.8% |
| Q4 FY2024 | Dec 31, 2024 | $18.22M | +73.7% |
| Q3 FY2024 | Sep 30, 2024 | $17.96M | +73.6% |
| Q2 FY2024 | Jun 30, 2024 | $13.47M | -61.6% |
| Q1 FY2024 | Mar 31, 2024 | $3.75M | -60.9% |
| Q4 FY2023 | Dec 31, 2023 | $10.49M | +21.7% |
| Q3 FY2023 | Sep 30, 2023 | $10.35M | -27.1% |
| Q2 FY2023 | Jun 30, 2023 | $35.08M | +300.7% |
| Q1 FY2023 | Mar 31, 2023 | $9.59M | -40.4% |
| Q4 FY2022 | Dec 31, 2022 | $8.62M | +0.8% |
| Q3 FY2022 | Sep 30, 2022 | $14.18M | +17.7% |
| Q2 FY2022 | Jun 30, 2022 | $8.75M | +36.2% |
| Q1 FY2022 | Mar 31, 2022 | $16.09M | +42.1% |
| Q4 FY2021 | Dec 31, 2021 | $8.55M | -56.1% |
| Q3 FY2021 | Sep 30, 2021 | $12.05M | -44.3% |
| Q2 FY2021 | Jun 30, 2021 | $6.43M | -63.8% |
| Q1 FY2021 | Mar 31, 2021 | $11.32M | -20.6% |
| Q4 FY2020 | Dec 31, 2020 | $19.50M | +59.2% |
| Q1 FY2020 | Mar 31, 2020 | $21.65M | +107.4% |
| Q4 FY2019 | Dec 31, 2019 | $17.76M | -34.3% |
| Q3 FY2019 | Sep 30, 2019 | $14.25M | +2049.0% |
| Q2 FY2019 | Jun 30, 2019 | $12.25M | +510.5% |
| Q1 FY2019 | Mar 31, 2019 | $10.44M | +129.3% |
| Q4 FY2018 | Dec 31, 2018 | $27.02M | +527.6% |
| Q3 FY2018 | Sep 30, 2018 | $663.00K | -91.2% |
| Q2 FY2018 | Jun 30, 2018 | $2.01M | -68.4% |
| Q1 FY2018 | Mar 31, 2018 | $4.55M | +57.6% |
| Q4 FY2017 | Dec 31, 2017 | $4.31M | +106.9% |
| Q3 FY2017 | Sep 30, 2017 | $7.53M | +61.2% |
| Q2 FY2017 | Jun 30, 2017 | $6.36M | +259.4% |
| Q1 FY2017 | Mar 31, 2017 | $2.89M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.08M | – |
| Q3 FY2016 | Sep 30, 2016 | $4.67M | – |
| Q2 FY2016 | Jun 30, 2016 | $1.77M | – |
See a number that looks wrong?